Cargando…

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis

Objective To examine the safety of using aliskiren combined with agents used to block the renin-angiotensin system. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Medline, Embase, the Cochrane Library, and two trial registries, published up to 7 May 2011. St...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harel, Ziv, Gilbert, Cameron, Wald, Ron, Bell, Chaim, Perl, Jeff, Juurlink, David, Beyene, Joseph, Shah, Prakesh S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253766/ https://www.ncbi.nlm.nih.gov/pubmed/22232539 http://dx.doi.org/10.1136/bmj.e42

Ejemplares similares

Evaluation of deficiencies in current discharge summaries for dialysis patients in Canada
por: Harel, Ziv, et al.
Publicado: (2012)

Barriers to guideline mandated renin–angiotensin inhibitor use: focus on hyperkalaemia
por: Vijayakumar, Shilpa, et al.
Publicado: (2019)

In pursuit of balance: renin–angiotensin–aldosterone system inhibitors and hyperkalaemia treatment
por: Sciatti, Edoardo, et al.
Publicado: (2023)

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
por: Verdecchia, Paolo, et al.
Publicado: (2008)

Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
por: Andersen, Karl
Publicado: (2009)

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
por: Sureshkumar, Kalathil K
Publicado: (2008)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Aliskiren: An orally active renin inhibitor
por: Wal, Pranay, et al.
Publicado: (2011)

Direct Renin Inhibition: Focus on Aliskiren
por: Pool, James L.
Publicado: (2007)

Direct Renin Inhibitor: Aliskiren in Chronic Kidney Disease
por: Morishita, Yoshiyuki, et al.
Publicado: (2012)

Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction
por: Farhadi, Susan A. S., et al.
Publicado: (2019)

Aliskiren in Patients Failing to Achieve Blood Pressure Targets With Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers
por: Hawkins, Elizabeth B., et al.
Publicado: (2012)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients
por: Morishita, Yoshiyuki, et al.
Publicado: (2012)

Renin Inhibition with Aliskiren: A Decade of Clinical Experience
por: Pantzaris, Nikolaos-Dimitrios, et al.
Publicado: (2017)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Aliskiren suppresses the renin–angiotensin–aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension
por: Morishita, Yoshiyuki, et al.
Publicado: (2012)

Aliskiren has chondroprotective efficacy in a rat model of osteoarthritis through suppression of the local renin-angiotensin system
por: Yan, Kaizhong, et al.
Publicado: (2017)

Frequency and factors influencing publication of abstracts presented at three major nephrology meetings
por: Harel, Ziv, et al.
Publicado: (2011)

Risk prediction models for contrast induced nephropathy: systematic review
por: Silver, Samuel A, et al.
Publicado: (2015)

Effects of Aliskiren on Stroke in Rats Expressing Human Renin and Angiotensinogen Genes
por: Schmerbach, Kristin, et al.
Publicado: (2010)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review
por: Rossignol, Patrick, et al.
Publicado: (2019)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Antidepressant-like Effects of Renin Inhibitor Aliskiren in an Inflammatory Mouse Model of Depression
por: Alzarea, Sami I., et al.
Publicado: (2022)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

The Prevalence of Acute Kidney Injury in Patients Hospitalized With COVID-19 Infection: A Systematic Review and Meta-analysis
por: Silver, Samuel A., et al.
Publicado: (2020)

Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease
por: Ohsawa, Masato, et al.
Publicado: (2013)

Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease
por: Li, Szu-yuan, et al.
Publicado: (2012)

Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study
por: Volterrani, Maurizio, et al.
Publicado: (2020)

Successful Treatment of Hypertension in Anuric Hemodialysis Patients with a Direct Renin Inhibitor, Aliskiren
por: Maeda, Yoshitaka, et al.
Publicado: (2011)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
por: Caminhotto, R de O., et al.
Publicado: (2016)

Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2
por: Lévy, Bernard I., et al.
Publicado: (2020)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2i23t6d35556276caad7e8qrs3